FTC says Shkreli breached lifetime pharma ban
CNBC · RSS · · AI-summarised by FinFlash
The FTC and a group of states filed a contempt claim alleging Martin Shkreli violated his lifetime ban from the pharmaceutical industry. Shkreli was barred after a trial found he organized an illegal scheme to perpetuate a monopoly for the drug Daraprim. The filing seeks to hold him accountable for conduct that regulators say breaches that court-ordered prohibition.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.